Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
Belgium
/
Pharmaceuticals & Biotech
Create a narrative
argenx Community
ENXTBR:ARGX Community
1
Narratives
written by author
0
Comments
on narratives written by author
23
Fair Values set
on narratives written by author
Create a narrative
argenx
Popular
Undervalued
Overvalued
Community Investing Ideas
argenx
AN
AnalystConsensusTarget
Consensus Narrative from 16 Analysts
Prefilled Syringe Launch And Pipeline Trials Will Expand Global Reach
Key Takeaways Strong pipeline potential from advanced Phase III and proof-of-concept studies could drive new product approvals and market expansion, boosting revenues. Planned launches and market expansions, including new VYVGART indications, could broaden global market presence and enhance financial health.
View narrative
€680.44
FV
16.5% undervalued
intrinsic discount
38.44%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
3 days ago
author updated this narrative
Your Valuation for
ARGX
ARGX
argenx
Your Fair Value
€
Current Price
€568.00
34.8% undervalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
-710m
6b
2015
2018
2021
2024
2025
2027
2030
Revenue US$6.2b
Earnings US$2.3b
Advanced
Set Fair Value